# Drugs Made In America Acquisition Corp. (DMAAU) — merger/definitive [completed]
Source: SEC API (secapi.ai) · situation sit_0861c97d73ec41012813 · retrieved 2026-08-11T16:09:10.240Z

## Overview
Power Analytics Global Corp. is a Delaware corporation engaged in the business of artificial intelligence, advanced analytics, and quantum-resistant security solutions.

Drugs Made In America Acquisition Corp. (DMAA), a Cayman Islands SPAC, and Power Analytics Global Corp. (PAGC), a Delaware corporation engaged in artificial intelligence, advanced analytics, and quantum-resistant security solutions, amended their Definitive Merger Agreement on July 14, 2026 (Amendment No. 3). The amendment requires the former sponsor to forfeit not less than 50% of founder shares and subject the remainder to earnout vesting (50% vesting at $12.50 closing price and 50% at $15.00, each for any 20 trading days within a 30-trading-day period after closing, with unvested shares forfeited on the fifth anniversary). The sponsor's 430,000 private placement rights are surrendered for no consideration, and 45,092 ordinary shares corresponding to the unfunded portion of the sponsor's private placement subscription are cancelled. The Company agreed to commence a cash tender offer for all outstanding publicly held rights at a price of not less than $0.25 and not more than $0.35 per right, funded solely from sources other than the Trust Account. The minimum-cash provisions were restated to provide for a target of $30,000,000 and a floor of $15,000,000. The Outside Date for closing is February 26, 2027, with the business combination deadline extended through April 29, 2027.

## Terms
- Counterparty: Power Analytics Global Corp. · Deal value: $3.00B · Consideration: stock · Price/share: $10

## Key dates
- Expiry 2027-04-29 · Expected close 2027-02-26 · Completed 2026-07-20

## Timeline
- 2026-07-20 · 8-K (0001213900-26-079678): 8-K - Drugs Made In America Acquisition Corp. — *Drugs Made In America Acquisition Corp. is a Cayman Islands exempted company and blank-check acquisition vehicle engaged in a business combination with Power Analytics Global Corp, a Delaware corporation engaged in artificial intelligence, advanced analytics, and quantum-resistant security solutions.* On July 14, 2026, Drugs Made In America Acquisition Corp. (DMAA) and Power Analytics Global Corp (PAGC) approved Omnibus Amendment No. 3 to their Definitive Merger Agreement dated April 29, 2026. The amendment restructures founder share treatment (requiring forfeiture of at least 50% and earnout vesting of the remainder based on stock price milestones of $12.50 and $15.00), addresses rights conversion through a cash tender offer ($0.25–$0.35 per right) or consent solicitation, and restates the minimum-cash provisions to a target of $30,000,000 and a floor of $15,000,000. The parties also pre-approved a contingent Amendment No. 4 (effective only if a definitive letter of intent with an additional target is executed by September 30, 2026) that would restructure the business combination into a three-party transaction with a combined equity value of $3,000,000,000 for PAGC and the additional target. The amendment implements related-party protections, including a fairness opinion requirement, due to common principal ownership between PAGC and BV Advisory Partners, LLC.
  https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-079678.txt
- 2026-07-20 · 425 (0001213900-26-079686): 425 - Drugs Made In America Acquisition Corp. — *Power Analytics Global Corp. is a Delaware corporation engaged in the business of artificial intelligence, advanced analytics, and quantum-resistant security solutions.* Drugs Made In America Acquisition Corp. (DMAA), a Cayman Islands SPAC, and Power Analytics Global Corp. (PAGC), a Delaware corporation engaged in artificial intelligence, advanced analytics, and quantum-resistant security solutions, amended their Definitive Merger Agreement on July 14, 2026 (Amendment No. 3). The amendment requires the former sponsor to forfeit not less than 50% of founder shares and subject the remainder to earnout vesting (50% vesting at $12.50 closing price and 50% at $15.00, each for any 20 trading days within a 30-trading-day period after closing, with unvested shares forfeited on the fifth anniversary). The sponsor's 430,000 private placement rights are surrendered for no consideration, and 45,092 ordinary shares corresponding to the unfunded portion of the sponsor's private placement subscription are cancelled. The Company agreed to commence a cash tender offer for all outstanding publicly held rights at a price of not less than $0.25 and not more than $0.35 per right, funded solely from sources other than the Trust Account. The minimum-cash provisions were restated to provide for a target of $30,000,000 and a floor of $15,000,000. The Outside Date for closing is February 26, 2027, with the business combination deadline extended through April 29, 2027.
  https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-079686.txt

## Citations
- 0001213900-26-079678 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026079678
- 0001213900-26-079686 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026079686